How would you approach a patient considered to be unfit for cystectomy with recurrent NMIBC refractory to BCG, failed pembrolizumab and unable to do more intravesical Rx?

Topics: Radiation Oncology • Genitourinary Cancers • Bladder Cancer • Medical Oncology • Urologic Oncology

Answer from: Medical Oncologist at Academic Institution

This seems to be a very difficult scenario, what are the reasons for not being able to pursue intravesical therapies? Nadofaragene firadenovec just got FDA approval, while there have been data with intravesical gemcitabine/docetaxel. We are waiting for the FDA decision on N-803/BCG combo (QUILT-3.03...

Comments

Medical Oncologist at Oncology Consultants
Thank you for the thorough explanation, the urolog...

Medical Oncologist at Rutgers Cancer Institute of New Jersey
I wholeheartedly agree that it is therapies that f...

Answer from: Medical Oncologist at Academic Institution

Agree with Dr. @Grivas. If not able to proceed with cystectomy or further intravesical therapy, the use of trimodality therapy based on RTOG 0926 is reasonable acknowledging the limitations of the data, most notably the small sample size. The trial is promising with the 3-year freedom from cystectom...

Comments

Medical Oncologist at AdventHealth Cancer Institute
Agree with Drs. @Grivas & @Milowsky! Although ...

Related Questions